Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?

J Thorac Oncol. 2023 Aug;18(8):964-966. doi: 10.1016/j.jtho.2023.05.002.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Exons
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Quinazolines / therapeutic use
  • Receptor, ErbB-2 / genetics

Substances

  • HM781-36B
  • Quinazolines
  • Receptor, ErbB-2